• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗癌钌(III)配合物KP1019通过肌浆网钙ATP酶(SERCA)干扰ATP依赖性Ca2+转运。

Anticancer ruthenium(III) complex KP1019 interferes with ATP-dependent Ca2+ translocation by sarco-endoplasmic reticulum Ca2+-ATPase (SERCA).

作者信息

Sadafi Fabrizio-Zagros, Massai Lara, Bartolommei Gianluca, Moncelli Maria Rosa, Messori Luigi, Tadini-Buoninsegni Francesco

机构信息

Department of Chemistry "Ugo Schiff", University of Florence, Via della Lastruccia 3, 50019 Sesto Fiorentino (Italy); Institute of Particle Technology, University of Erlangen-Nuremberg, 91058 Erlangen (Germany).

出版信息

ChemMedChem. 2014 Aug;9(8):1660-4. doi: 10.1002/cmdc.201402128. Epub 2014 Jun 11.

DOI:10.1002/cmdc.201402128
PMID:24920093
Abstract

Sarco-endoplasmic reticulum Ca2+-ATPase (SERCA), a P-type ATPase that sustains Ca2+ transport and plays a major role in intracellular Ca2+ homeostasis, represents a therapeutic target for cancer therapy. Here, we investigated whether ruthenium-based anticancer drugs, namely KP1019 (indazolium [trans-tetrachlorobis(1H-indazole)ruthenate(III)]), NAMI-A (imidazolium [trans-tetrachloro(1H-imidazole)(S-dimethylsulfoxide)ruthenate(III)]) and RAPTA-C ([Ru(η6-p-cymene)dichloro(1,3,5-triaza-7-phosphaadamantane)]), and cisplatin (cis-diammineplatinum(II) dichloride) might act as inhibitors of SERCA. Charge displacement by SERCA adsorbed on a solid-supported membrane was measured after ATP or Ca2+ concentration jumps. Our results show that KP1019, in contrast to the other metal compounds, is able to interfere with ATP-dependent translocation of Ca2+ ions. An IC50 value of 1 μM was determined for inhibition of calcium translocation by KP1019. Conversely, it appears that KP1019 does not significantly affect Ca2+ binding to the ATPase from the cytoplasmic side. Inhibition of SERCA at pharmacologically relevant concentrations may represent a crucial aspect in the overall pharmacological and toxicological profile of KP1019.

摘要

肌质网钙-ATP酶(SERCA)是一种P型ATP酶,可维持钙离子运输并在细胞内钙离子稳态中起主要作用,是癌症治疗的一个靶点。在此,我们研究了钌基抗癌药物,即KP1019(吲唑盐[反式-四氯双(1H-吲唑)钌(III)])、NAMI-A(咪唑盐[反式-四氯(1H-咪唑)(S-二甲亚砜)钌(III)])和RAPTA-C([Ru(η6-对异丙基苯)二氯(1,3,5-三氮杂-7-磷杂金刚烷)])以及顺铂(顺式-二氨合铂(II)二氯化物)是否可能作为SERCA的抑制剂。在ATP或钙离子浓度跃升后,测量吸附在固体支持膜上的SERCA的电荷位移。我们的结果表明,与其他金属化合物不同,KP1019能够干扰钙离子的ATP依赖性转运。测定出KP1019抑制钙离子转运的IC50值为1 μM。相反,似乎KP1019不会显著影响钙离子从细胞质一侧与ATP酶的结合。在药理学相关浓度下抑制SERCA可能是KP1019整体药理学和毒理学特性的一个关键方面。

相似文献

1
Anticancer ruthenium(III) complex KP1019 interferes with ATP-dependent Ca2+ translocation by sarco-endoplasmic reticulum Ca2+-ATPase (SERCA).抗癌钌(III)配合物KP1019通过肌浆网钙ATP酶(SERCA)干扰ATP依赖性Ca2+转运。
ChemMedChem. 2014 Aug;9(8):1660-4. doi: 10.1002/cmdc.201402128. Epub 2014 Jun 11.
2
EPR as a probe of the intracellular speciation of ruthenium(III) anticancer compounds.电子顺磁共振(EPR)作为研究钌(III)抗癌化合物细胞内形态的探针。
Metallomics. 2013 Dec;5(12):1624-33. doi: 10.1039/c3mt00090g. Epub 2013 Sep 20.
3
Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and antiproliferative activity.NAMI-A型配合物(HL)[反式-四氯钌(III)L(S-二甲基亚砜)](L =咪唑、吲唑、1,2,4-三唑、4-氨基-1,2,4-三唑和1-甲基-1,2,4-三唑)的构效关系:水合作用、氧化还原性质、蛋白质结合及抗增殖活性
J Med Chem. 2007 May 3;50(9):2185-93. doi: 10.1021/jm061081y. Epub 2007 Apr 3.
4
Ruthenium anticancer agent KP1019 binds more tightly than NAMI-A to tRNA.钌类抗癌药物 KP1019 与 tRNA 的结合比 NAMI-A 更紧密。
J Inorg Biochem. 2018 May;182:177-183. doi: 10.1016/j.jinorgbio.2018.02.019. Epub 2018 Feb 24.
5
The Deceptively Similar Ruthenium(III) Drug Candidates KP1019 and NAMI-A Have Different Actions. What Did We Learn in the Past 30 Years?看似相似的钌(III)候选药物KP1019和NAMI-A具有不同作用。在过去30年里我们学到了什么?
Met Ions Life Sci. 2018 Feb 5;18. doi: 10.1515/9783110470734-011.
6
Influence of ascorbic acid on the activity of the investigational anticancer drug KP1019.抗坏血酸对研究性抗癌药物 KP1019 活性的影响。
J Biol Inorg Chem. 2011 Dec;16(8):1205-15. doi: 10.1007/s00775-011-0809-4. Epub 2011 Jun 26.
7
RNA binding and inhibition of primer extension by a Ru(III)/Pt(II) metal complex.Ru(III)/Pt(II) 金属配合物的 RNA 结合和引物延伸抑制作用。
Chem Commun (Camb). 2013 Jun 4;49(44):5031-3. doi: 10.1039/c3cc40699g. Epub 2013 Apr 24.
8
Molecular mass spectrometry in metallodrug development: a case of mapping transferrin-mediated transformations for a ruthenium(III) anticancer drug.金属药物研发中的分子质谱分析:以绘制转铁蛋白介导的钌(III)抗癌药物转化过程为例
Anal Chim Acta. 2014 Dec 3;851:72-7. doi: 10.1016/j.aca.2014.08.031. Epub 2014 Aug 21.
9
Intrinsic and acquired forms of resistance against the anticancer ruthenium compound KP1019 [indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] (FFC14A).针对抗癌钌化合物KP1019 [吲唑鎓反式-[四氯双(1H-吲唑)钌(III)] (FFC14A) 的内在和获得性耐药形式。
J Pharmacol Exp Ther. 2005 Jan;312(1):281-9. doi: 10.1124/jpet.104.073395. Epub 2004 Aug 26.
10
Cellular uptake and subcellular distribution of ruthenium-based metallodrugs under clinical investigation versus cisplatin.临床研究中顺铂与基于钌的金属药物的细胞摄取和亚细胞分布。
Metallomics. 2011 Jun;3(6):591-9. doi: 10.1039/c0mt00101e. Epub 2011 Mar 11.

引用本文的文献

1
ER Stress Response and Induction of Apoptosis in Malignant Pleural Mesothelioma: The Achilles Heel Targeted by the Anticancer Ruthenium Drug BOLD-100.内质网应激反应与恶性胸膜间皮瘤中细胞凋亡的诱导:抗癌钌药物BOLD-100的致命弱点靶点
Cancers (Basel). 2022 Aug 26;14(17):4126. doi: 10.3390/cancers14174126.
2
Endoplasmic Reticulum Calcium Pumps and Tumor Cell Differentiation.内质网钙泵与肿瘤细胞分化。
Int J Mol Sci. 2020 May 9;21(9):3351. doi: 10.3390/ijms21093351.
3
Label-Free Bioelectrochemical Methods for Evaluation of Anticancer Drug Effects at a Molecular Level.
无标记生物电化学方法在分子水平上评估抗癌药物的效果。
Sensors (Basel). 2020 Mar 25;20(7):1812. doi: 10.3390/s20071812.
4
High in Vitro and in Vivo Tumor-Selective Novel Ruthenium(II) Complexes with 3-(2'-Benzimidazolyl)-7-fluoro-coumarin.含3-(2'-苯并咪唑基)-7-氟香豆素的新型高体外和体内肿瘤选择性钌(II)配合物
ACS Med Chem Lett. 2019 May 22;10(6):936-940. doi: 10.1021/acsmedchemlett.9b00098. eCollection 2019 Jun 13.
5
Drug Interactions With the Ca-ATPase From Sarco(Endo)Plasmic Reticulum (SERCA).药物与肌浆(内质)网Ca-ATP酶(SERCA)的相互作用。
Front Mol Biosci. 2018 Apr 11;5:36. doi: 10.3389/fmolb.2018.00036. eCollection 2018.
6
A systematic assessment of chemical, genetic, and epigenetic factors influencing the activity of anticancer drug KP1019 (FFC14A).对影响抗癌药物KP1019(FFC14A)活性的化学、遗传和表观遗传因素的系统评估。
Oncotarget. 2017 Sep 30;8(58):98426-98454. doi: 10.18632/oncotarget.21416. eCollection 2017 Nov 17.
7
Electrophysiological characterization of the archaeal transporter NCX_Mj using solid supported membrane technology.利用固体支持膜技术对古菌转运体NCX_Mj进行电生理学特性分析。
J Gen Physiol. 2016 Jun;147(6):485-96. doi: 10.1085/jgp.201611587.
8
Editorial of Special Issue Ruthenium Complex: The Expanding Chemistry of the Ruthenium Complexes.专题编辑:钌配合物:钌配合物不断扩展的化学性质
Molecules. 2015 Sep 18;20(9):17244-74. doi: 10.3390/molecules200917244.